Project Portfolio
alytas therapeutics GmbH was founded in 2018 as a spin-off from the University of Jena and is based in Jena, Germany. The founders are experts in lipid-associated metabolic disorders and related comorbidities (such as obesity).
alytas therapeutics GmbH is dedicated to developing new therapeutic targets for the treatment of obesity. The company is currently working closely with the University Hospital Jena (Germany) and CureDiab GmbH in Düsseldorf. Given the current epidemic increase in obesity and the associated comorbidities, there is a high demand for innovative therapies. alytas therapeutics focuses on the sustainable elimination of fat cells relevant to the comorbidities, in combination with weight loss.
Baliopharm AG was founded in 2007 and is based in Reinach, Switzerland.
In April 2022, Baliopharm successfully completed Phase 1 clinical trials with the antibody Atrosimab, an antagonist of the TNFR1 receptor. Atrosimab is suitable for the treatment of a variety of acute and chronic inflammatory diseases. Xlife Sciences does not hold any equity interest in Baliopharm AG but instead receives a specific percentage of the annual net revenue that Baliopharm generates from the sale or licensing of Atrosimab.
Ix Therapeutics GmbH is a joint venture founded by Xlife Sciences AG and Indivumed GmbH in March 2021.
Ix Therapeutics GmbH is dedicated to identifying therapeutic antibodies for oncological indications based on multiomics patient data. Ix Therapeutics is a joint venture between Xlife Sciences AG and the Hamburg-based oncology company Indivumed. The therapeutic antibodies are identified using Veraxa's screening technology.
Lysatpharma GmbH is a German biotechnology company founded in 2018 and based in Jena, Germany.
Lysatpharma focuses on regenerative medicine and new biomedical immunotherapies based on extracellular vesicles (exosomes). In collaboration with the University Hospital Jena (Germany), the company is developing novel immunotherapies for acute and chronic systemic inflammatory diseases. Lysatpharma has a patented technology for purifying exosomes from blood donations. The exosomes derived from platelets have immunomodulatory and regenerative properties. They are being developed as a therapy for inflammatory diseases.
Emerged from panmabs GmbH, Firstgene is opening a new chapter in next-generation gene therapy. The focus is on the development of an innovative gene therapy approach that enables targeted gene expression in the target cells.
Firstgene Life Sciences GmbH focuses on the development of innovative, tissue‑specific gene therapies. This work is based on a licensing agreement with Hovione, a leading European CDMO, which provides access to the relevant key technology.
The underlying technology enables highly selective gene therapy of the target tissue, thereby addressing a key efficiency and safety challenge of existing approaches. The initial target indication is hepatocellular carcinoma (HCC), an indication with high unmet medical need and a five‑year survival rate of less than 20%.
QUADIRA BIOSCIENCES AG was incorporated on 17 March 2021 and has its registered seat in Solothurn,Switzerland.
QUADIRA BIOSCIENCES AG was founded on March 17, 2021, and is based in Solothurn, Switzerland. QUADIRA BIOSCIENCES AG, a joint venture between Anfass Life Technologies AG and Xlife Sciences AG, leverages the technologies of abc biopply and Veraxa to improve antibody-drug conjugates (ADCs) for the treatment of oncological indications. The combination of both technologies enables the company to develop innovative, highly effective ADCs with higher cytotoxic activity and simultaneously improved side effect profiles for cancer therapy in a significantly shortened preclinical phase, largely avoiding the need for animal testing.
xarma life sciences GmbH was founded in 2020 and is based in Mainz, Germany.
xarma life sciences aims to develop top-tier functional and modulatory agents for the treatment of circulatory, immunological, and oncogenic diseases with unmet medical needs.
XRNA Biotech GmbH was founded in 2022 and is based in Zurich, Switzerland.
XRNA is dedicated to researching various RNA molecules for targeted therapeutic applications in oncology. The company is currently in licensing negotiations with several renowned universities.
